TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients

EBioMedicine

Volumn 2, Issue 8, 2015, Pages 825-830

  Kandioler, Daniela ^a   Mittlböck, Martina ^a   Kappel, Sonja ^a   Puhalla, Harald ^a   Herbst, Friedrich ^b   Langner, Cord ^c   Wolf, Brigitte ^a   Tschmelitsch, Jörg ^b   Schippinger, Walter ^a   Steger, Günther ^a   Hofbauer, Friedrich ^d   Samonigg, Hellmut ^c   Gnant, Michael ^a   Teleky, Bela ^a   Kührer, Irene ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Krankenhaus Oberpullendorf   (Austria)

Author keywords

Adjuvant 5 fluorouracil; Predictive biomarker; Stage III colon cancer; TP53; Varying treatment efficacy

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; LEVAMISOLE; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; YOUNG ADULT; ADOLESCENT; COLONIC NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENETICS; MORTALITY; MUTATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84951573671     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.06.003     Document Type: Article

References (27)

1. Ahmed I.A., Kelly S.B., Anderson J.J., Angus B., Challen C., Lunec J. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. Colorectal Dis. 2008, 10(4):344-351.
2. Akiyama J., Alexandre L., Baruah A., et al. Strategy for prevention of cancers of the esophagus. Ann. N. Y. Acad. Sci. 2014, 1325:108-126.
3. Bleeker W.A., Hayes V.M., Karrenbeld A., et al. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis. Colon Rectum 2001, 44(3):358-363.
4. Brenner H., Kloor M., Pox C.P. Colorectal cancer. Lancet 2014, 383(9927):1490-1502.
5. Cassidy J., Clarke S., Diaz-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 2008, 26(12):2006-2012.
6. Chau I., Cunningham D. Adjuvant therapy in colon cancer-what, when and how?. Ann. Oncol. 2006, 17(9):1347-1359.
7. den Dunnen J.T., Antonarakis S.E. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 2000, 15(1):7-12.
8. Denoix P.F., Schwartz D. General rules for classification of cancers and presentation of the therapeutic results. Mem. Acad. Chir. 1959, 85(15-16):415-424.
9. Edlund K., Larsson O., Ameur A., et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(24):9551-9556.
10. Elsaleh H., Powell B., McCaul K., et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res. 2001, 7(5):1343-1349.
11. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J. Clin. Oncol. 2004, 22(10):1797-1806.
12. Greene F.L., Stewart A.K., Norton H.J. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann. Surg. 2002, 236(4):416-421. (discussion 21).
13. Greene F.L., Page D.L., Fleming I.D., et al. AJCC Cancer Staging Manual 2002, Springer, New York, NY. 6th ed.
14. Gunderson L.L., Jessup J.M., Sargent D.J., Greene F.L., Stewart A.K. Revised TN categorization for colon cancer based on national survival outcomes data. J. Clin. Oncol. 2010, 28(2):264-271.
15. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009, 27(5):672-680.
16. Iacopetta B. TP53 mutation in colorectal cancer. Hum. Mutat. 2003, 21(3):271-276.
17. Kato S., Han S.Y., Liu W., et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(14):8424-8429.
18. Munro A.J., Lain S., Lane D.P. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br. J. Cancer 2005, 92(3):434-444.
19. Petersen S., Thames H.D., Nieder C., Petersen C., Baumann M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis. Colon Rectum 2001, 44(3):322-333. (discussion 33-4).
20. Petitjean A., Mathe E., Kato S., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28(6):622-629.
21. Pilat N., Grünberger T., Längle F., et al. Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study. EJSO 2015, 41:683-689.
22. Roth A.D., Delorenzi M., Tejpar S., et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J. Natl. Cancer Inst. 2012, 104(21):1635-1646.
23. Russo A., Bazan V., Iacopetta B., et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 2005, 23(30):7518-7528.
24. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008, 26(12):2013-2019.
25. Schippinger W., Jagoditsch M., Sorre C., et al. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br. J. Cancer 2005, 92(9):1655-1662.
26. Soussi T., Asselain B., Hamroun D., et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin. Cancer Res. 2006, 12(1):62-69.
27. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360(6):563-572.